The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Correlates of overall survival (OS) in metastatic uveal melanoma (mUM) and a randomized trial of cabozantinib (cabo) versus chemotherapy (chemo).
 
Daniel Olson
No Relationships to Disclose
 
Riyue Bao
No Relationships to Disclose
 
Jacob B Allred
No Relationships to Disclose
 
Carrie Strand
No Relationships to Disclose
 
Yuanyuan Zha
No Relationships to Disclose
 
Timothy C. Carll
No Relationships to Disclose
 
Brian Labadie
No Relationships to Disclose
 
Bruno R. Bastos
Honoraria - AstraZeneca; Takeda; Takeda
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Immunocore; Immunovaccine; Merck; Novartis
Research Funding - Merck; Takara Bio
Expert Testimony - Merck
 
Pamela N. Munster
Stock and Other Ownership Interests - OncoSec (I)
Honoraria - Amgen (I); Prometheus (I); Threshold Pharmaceuticals
Consulting or Advisory Role - HUYA Bioscience International
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst)
 
Gary K. Schwartz
Stock and Other Ownership Interests - Abbott; Abbvie; Becton Dickinson; Bristol-Myers Squibb; GlaxoSmithKline; Johnson & Johnson; Merck; Pfizer
Honoraria - Array BioPharma; Bayer; Daiichi Sankyo; DarwinHealth; Ellipses Pharma; Fortress Biotech; Human Longevity, Inc; Iovance Biotherapeutics; Pfizer; PTC Therapeutics; PureTech
Consulting or Advisory Role - Array BioPharma; Bayer; Bionaut Labs; Daiichi Sankyo; DarwinHealth; Ellipses Pharma; Fortress Biotech; Gencirq; Human Longevity, Inc; Iovance Biotherapeutics; Pfizer; PTC Therapeutics; PureTech
Research Funding - Astex Pharmaceuticals; Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Fortress Biotech (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
Travel, Accommodations, Expenses - Array BioPharma; Daiichi Sankyo; Iovance Biotherapeutics; PTC Therapeutics; PureTech
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Actym Therapeutics; Aduro Biotech; Alphamab; Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; Compugen; EMD Serono; Gilead Sciences; IDEAYA Biosciences; Janssen; Jounce Therapeutics; Mavu Pharmaceutical; Merck; Newlink Genetics; Novartis; Reflexion Medical; Spring Bank; Syndax; Tempest Therapeutics; TTC Oncology; Vividion Therapeutics; WntRx Pharmaceuticals
Research Funding - Abbvie (Inst); Array BioPharma; Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Checkmate Pharmaceuticals; Compugen (Inst); Corvus Pharmaceuticals (Inst); Delcath Systems (Inst); Evelo Therapeutics; Five Prime Therapeutics (Inst); FLX Bio; Genentech/Roche (Inst); Immunocore (Inst); Incyte (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Palleon Pharmaceuticals; Pharmacyclics (Inst); Tesaro (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; EMD Serono; Gilead Sciences; IDEAYA Biosciences; Janssen; Jounce Therapeutics; Merck; Novartis; Reflexion Medical